DexCom stock has delivered a decline of about 35% over the past 5 years, yet a Discounted Cash Flow (DCF) intrinsic value estimate currently points to meaningful upside compared with the recent US$88.96 share price. At the same time, the broader valuation checks lean expensive overall, which leaves investors weighing a discounted intrinsic estimate against a weaker score on other metrics.

• Over the past 5 years, DexCom shares are down roughly 35%, which means long term holders have so far not been rewarded despite more recent gains.
• Expectations that DexCom can keep growing its continuous glucose monitoring business and expand free cash flow may support the intrinsic value case. However, any slowdown in growth or pressure on margins could quickly undermine that upside.
• On a wider set of valuation checks, DexCom scores 2 out of 6, which suggests the stock does not screen as a clear bargain even though it does not look expensive on every measure.

The issue now is whether the current discount to the DCF intrinsic value is enough to compensate investors for a mixed broader valuation picture and a weak long term return record.

Compare DexCom's mixed long term record and DCF upside with other potential opportunities by scanning our hand picked list of 51 high quality undervalued stocks.

Is DexCom a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model estimates what DexCom could be worth based on its projected future cash generation. For DexCom, the latest twelve month free cash flow is about $1.38b, and the model assumes that cash flows continue growing from this base rather than shrinking or recovering from a low point.

On these assumptions, the DCF suggests an intrinsic value of about $141 per share compared with the recent $88.96 share price. This implies the stock screens around 37.1% undervalued on this measure. Because recent coverage has highlighted DexCom as a growth compounder with expanding free cash flow margins, the current discount may reflect the market waiting to see whether that cash generation can be maintained over time.

On this cash flow view, DexCom stock appears undervalued relative to the level of free cash it is currently producing.

Our Discounted Cash Flow (DCF) analysis suggests DexCom is undervalued by 37.1%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Where Does DexCom Sit on Earnings?

P/E is a useful check for DexCom because the stock already has positive earnings that investors can compare with other medical equipment companies.

DexCom currently trades on a P/E of about 33.6x, which is higher than the Medical Equipment industry average of roughly 26.6x and above the peer group average of about 26.5x. A fair P/E multiple based on DexCom's profile is estimated at around 32.4x, so the current valuation sits only slightly above that level rather than at a steep premium.

This indicates that the market is applying a modest premium to DexCom relative to the sector, but that premium is not far from what the tailored fair multiple implies, given the company’s characteristics and risk profile.

Overall, DexCom appears roughly fairly valued on its current P/E multiple compared with both peers and its modelled fair ratio.

The DexCom Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where DexCom's valuation puzzle leaves off. They spell out what mix of future growth, margins and earnings would need to play out for the stock to be worth materially more or materially less than today's price on the Community page. Each one links its number to a specific view on how DexCom's growth, profitability and risks might evolve, which you can revisit as new information comes through.

Community views on DexCom are split between those who see reimbursement gains as a support for upside and those who focus on adoption and margin risks.

Bull case: 5% undervalued

"The recent expansion of insurance reimbursement for type 2 non-insulin diabetes patients now covering nearly 6 million lives across the three largest U.S. PBMs opens a large, previously untapped segment of DexCom's addressable market, driving new patient growth and supporting robust multi-year revenue expansion..."

Bear case: 31% overvalued

"Although broader commercial coverage for type 2 diabetes patients not using insulin, including more than 6 million covered lives across large PBMs and an expected expansion to over 7 million with Prime Therapeutics, supports a larger addressable base, future revenue growth still depends on converting the roughly two thirds of covered patients who are not yet using CGM..."

Do you think there's more to the story for DexCom? Head over to our Community to see what others are saying!

The Bottom Line

DexCom presents a split message on valuation. The Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside, while the market multiple view sits closer to about right, and broader valuation checks look weak. That gap reflects a market that is cautious on how much growth and cash flow quality to price in today. The key question from here is whether DexCom can sustain cash generation and margins strongly enough for the current discount to be an opportunity rather than a value trap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.